National Community Pharmacists Association
FDARulemakingFDA-2015-N-0030

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

RIN
Last modified
May 18, 2026
Comment window
closed 1442d ago
National Community Pharmacists Association filings
6

Activity

National Community Pharmacists Association filed 6 comments on this docket between Sep 22, 2020 and May 21, 2024. 27 other organizations filed here. The comment window closed 1442d ago.

What National Community Pharmacists Association filed (6)

May 21, 2024· Comment from Alliance for Pharmacy Compounding & National Community Pharmacists Association· FDA-2015-N-0030-8518

Filed on regulations.gov — full text not in the inline record.

Apr 30, 2024· Comment from National Community Pharmacists Association (NCPA)· FDA-2015-N-0030-8517

Please see attached for NCPA's written statement for the record, ahead of FDA's listening session on compounding on May 14.

Apr 23, 2024· Comment from Alliance for Pharmacy Compounding and National Community Pharmacists Association· FDA-2015-N-0030-8516

Filed on regulations.gov — full text not in the inline record.

Jun 5, 2023· Comment from National Community Pharmacists Association· FDA-2015-N-0030-8515

Please see attached for our statement for the record, and two statements from members, for the June 15 FDA listening session on compounding.

Apr 7, 2022· Comment from Alliance for Pharmacy Compounding, APhA, National Community Pharmacists Association, and PCCA· FDA-2015-N-0030-8508

Filed on regulations.gov — full text not in the inline record.

Sep 22, 2020· Comment from Alliance for Pharmacy Compounding, National Community Pharmacists Association, and National Alliance of State Pharmacy Associations· FDA-2015-N-0030-8372

Please find the attached comment on the NASEM study on cBHT compounding submitted on behalf of APC, NCPA and NASPA

Abstract

Compounding of Human Drug Products

View on regulations.gov →